1,3-Dimethyl-1,6-dihydropyrazolo[3,4-c]pyrazole | 446276-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,3-Dimethyl-1,6-dihydropyrazolo[3,4-c]pyrazole
• 英文别名: 4,6-dimethyl-1H-pyrazolo[3,4-c]pyrazole
• CAS: 446276-19-3
• 化学式: C₆H₈N₄
• mdl: MFCD00238783
• 分子量: 136.15
• InChiKey: UDMCXTHYBBIVGB-UHFFFAOYSA-N

物化性质

• 熔点：
  218-220°C
• 沸点：
  301.3±22.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT

文献信息

• Substituted fused imidazoles and pyrazoles and use thereof
  申请人：BAYER INTELLECTUAL PROPERTY GMBH

  公开号：US20130210824A1

  公开（公告）日：2013-08-15

  The present application relates to novel substituted fused imidazoles and pyrazoles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof producing medicaments for the treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代融合咪唑和吡唑化合物，以及其制备方法，单独或组合使用，用于治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20170233413A1

  公开（公告）日：2017-08-17

  The present application relates to novel substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代融合嘧啶类化合物，以及其制备方法，其单独或与其他药物联合用于治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Brockunier Linda L.

  公开号：US20110218202A1

  公开（公告）日：2011-09-08

  Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.

  公式I的化合物能够调节体内环状鸟苷酸单磷酸（“cGMP”）的产生，一般适用于治疗和预防与cGMP平衡紊乱相关的疾病。此外，本发明还涉及制备公式I化合物的过程，以及它们用于治疗和预防上述疾病和制备药物的用途，以及包含公式I化合物的制药制剂。
• Substituted annellated pyrimidines and use thereof
  申请人：Bayer Intellectual Property GmbH

  公开号：US20150105374A1

  公开（公告）日：2015-04-16

  The present application relates to novel substituted annellated pyrimidines, methods for production thereof, use thereof alone or in combinations for treating and/or preventing diseases and use thereof for the production of medicinal products for treating and/or preventing diseases, in particular for treating and/or preventing cardiovascular diseases.

  本申请涉及新的取代的环并嘧啶，其制备方法，其单独或与其他药物联合治疗和/或预防疾病的用途以及用于生产治疗和/或预防疾病的药物制剂的用途，特别是用于治疗和/或预防心血管疾病。
• US8741910B2
  申请人：——

  公开号：US8741910B2

  公开（公告）日：2014-06-03